1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Beijing Centergate Technologies (Holding) Co., Ltd Class A

Beijing Centergate Technologies (Holding) Co., Ltd Class A

SSZSE:000931
4.06
CNY
0.00
(0.00%)
3.10BMarket Cap
Oct 30Next Earn
Beijing Centergate Technologies (Holding) Co., Ltd Class A
SZSE:000931
(Shenzhen Stock Exchange)

Recent

price

4.06

P/E

ratio

- -

div

yld

0.36%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.85
4.91
4.85
5.34
4.5
1.6
2.19
2.33
2.36
2.83
2.38
2.6
2.74
3.02
3.36
3.24
- -
Revenue per Share
0.02
0.06
0.04
-0.29
0.02
0.23
0.04
0.02
0.12
0.13
0.03
-0.15
-0.05
0.06
0.07
0.06
- -
Basic EPS, GAAP
0.23
0.31
-0.12
0.68
-0.68
-0.12
-0.13
0.04
0.1
0.03
0.08
0.26
0.16
0.2
0.02
-0.08
- -
Free Cash Flow per Basic Share
0.08
0.07
0.08
0.07
0.1
0.13
0.1
0.15
0.08
0.07
0.08
0.05
0.05
0.04
0.04
0.01
0.01
Dividend per Share
1.04
1.09
1.13
0.83
0.93
1.17
1.31
2.12
2.24
2.22
2.26
2.11
1.97
2.04
2.11
2.17
2.11
Book Value per Share
1.02
1.06
1.1
0.81
0.91
1.1
0.94
1.63
1.76
1.74
1.78
1.62
1.52
1.59
1.62
1.7
1.64
Tangible Book Value per Share
675
675
675
675
674
675
676
747
753
753
752
753
752
753
753
753
753
Basic Weighted Avg Shares
2,599
3,310
3,271
3,605
3,034
1,078
1,479
1,740
1,774
2,135
1,790
1,956
2,060
2,277
2,532
2,443
- -
Sales/Revenue/Turnover
3.47
3.12
3.17
1.42
1.8
3.3
8.36
7.3
5.75
9.08
8.27
0.69
5.63
7.46
8.12
7.24
- -
Operating Margin (%)
24
23
40
32
39
37
53
62
118
75
85
123
139
174
200
158
- -
Depreciation Expense
10
42
30
-197
14
152
27
14
93
95
25
-114
-40
49
54
48
- -
Net Income, GAAP
69.34
33.21
53.17
- -
65.15
8.68
31.7
34.8
23.55
23.89
32.08
- -
- -
25.04
37.19
41.85
- -
Effective Tax Rate (%)
0.4
1.26
0.91
-5.46
0.45
14.14
1.85
0.82
5.25
4.46
1.42
-5.83
-1.92
2.13
2.12
1.96
- -
Profit Margin (%)
382
144
284
-93
89
184
320
848
874
765
614
171
152
197
229
218
204
Working Capital
2
- -
187
2
140
30
290
229
225
211
215
403
530
381
372
485
505
LT Debt
875
792
830
635
692
858
1,067
1,791
1,893
1,857
1,911
1,813
1,677
1,736
1,807
1,855
1,814
Total Equity
0.47
0.38
2.09
- -
1.11
12.71
1.48
1.63
2.86
3.63
1.88
- -
- -
2.27
2.71
2.29
- -
Return on Invested Capital (%)
1.62
6.32
5.15
- -
3.26
16.63
4.02
1.31
3.89
3.91
1.29
- -
- -
2.85
2.39
2.21
- -
Return on Capital (%)
1.5
5.8
4
-29.74
2.31
21.48
3.27
1.15
5.67
5.67
1.51
-6.94
-2.58
3.22
3.43
2.97
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
643
663
626
LT Borrowings
39
66
88
LT Finance Leases
446
426
418
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
753
753
753
Market Capitalization
3,668
3,886
3,095

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,693
1,675
1,619
Cash, Cash Equivalents & STI
141
229
168
Accounts Receivable, Net
1,039
890
931
Inventories
187
168
192
Total Current Liabilities
1,475
1,436
1,415
Payables & Accruals
- -
- -
- -
ST Debt
643
663
626
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.65%
-0.47%
2.67%
Free Cash Flow
-25.9%
-79.87%
-511.3%
Net Income, GAAP
-48.41%
-167.25%
-10.65%
Sales/Revenue/Turnover
9.38%
6.57%
-3.52%
Total Cash Common Dividend
-14.13%
-27.67%
-82.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
606
667
656
602
2,532
2025
616
623
- -
561
2,443
2026
472
535
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.03
0.02
- -
0.07
2025
0.02
0.03
- -
- -
0.06
2026
-0.02
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
-0.02
0.01
2026
0.01
0.02
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) operates as a diversified healthcare and biomedicine company primarily engaged in pharmaceutical production and sales, alongside personal care products, elderly care services, commercial concrete, and other segments in China. Founded in 1999 and headquartered at Pengrun Building, No. 26 Xiaoyun Road, Beijing, China, the company offers a broad portfolio of pharmaceutical products including Anemarrhena saponin BII and capsules for vascular dementia; Naloxone Hydrochloride injection and Naltrexone Hydrochloride tablets for opioid-related treatments and ethanol poisoning relief; pain management solutions such as Hydrocodone acetaminophen tablets, Tramadol Hydrochloride injections and tablets, Oxycodone Hydrochloride injection and sustained-release tablets (40mg), and Aminophenol Tramadol tablets; respiratory and antiemetic therapies like Ambroxol Hydrochloride injection and Tropisetron Mesylate injection; cardiovascular medications including Metoprolol succinate API, Bisoprolol Fumarate tablets, Bisoprolol amlodipine tablets, and Benidipine Hydrochloride tablets; gout treatment with Febuxostat tablets; diabetes control via Glipizide Dispersible tablets; antifungal agents such as Bifonazole API and cream; cognitive enhancers like Huperzine A tablets; women's health products including Wujia Biochemical capsules and Clindamycin phosphate vaginal gel; probiotics such as Lactobacillus tablets; motion sickness prevention with Phencynonate Hydrochloride tablets; and additional items like Cediodine lozenges for pharyngitis, Piracetam injections, and Bromazepine Hydrochloride injections. In July 2024, the company adjusted its global strategy to focus on becoming a leading medical and health industry service provider, emphasizing CNI biomedicine, health products, nursing medical services, and commercial concrete; it signed a global strategic cooperation agreement with Hailai Technology in September 2024 to advance these objectives. Beijing Centergate Technologies maintains operations predominantly in China, with international reach in pharmaceuticals, employs approximately 2,267 people, and reports biomedicine as its largest revenue segment, followed by commercial concrete and elderly care.